Clinicn Investigator, Assc Prf MGBCI Faculty Heme Malig MGPO, Mass General Research Institute

Associate Physician Medicine-Hematology and Medical Oncology, Massachusetts General Hospital

Associate Professor of Medicine Harvard Medical School

MD Yale University School of Medicine 2004

acute myeloid leukemia; acute promyelocytic leukemia; antibody-drug conjugates; antigens cd30; antineoplastic agents; apoptosis; aurora kinase inhibition; carbazoles; cyclin-dependent kinases; eosinophilia; flt3 inhibition; fms-like tyrosine kinase 3; glutarates; isocitrate dehydrogenase; leukocytosis; myelodysplastic syndromes; protein kinase inhibitors

My research is focused on the development and clinical translation of novel therapies for acute leukemias.

I currently lead multiple clinical trials at the Dana Farber Harvard Cancer Center for patients with advanced leukemia and hematologic malignancies.

I have a specific interest in studying FLT3 inhibition, aurora kinase inhibition, and antibody-drug conjugates as novel therapies.